• RubrYc Therapeutics

  Participated · Series A · Aug 2021

  RubrYc Therapeutics applies proprietary machine-learning and computational biology solutions to discover epitope-selective mono- and bispecific antibodies using its Discovery Engine and Meso-scale Engineered Molecules. The company focuses on steering antibody discovery campaigns to particular epitopes on validated and challenging targets. RubrYc will partner with iBio to combine its discovery capabilities with iBio’s FastPharming manufacturing and development expertise; RubrYc is responsible for discovery while iBio will conduct preclinical, clinical and commercialization activities for selected candidates. iBio secured exclusive worldwide rights to advance RubrYc’s lead program, RTX-003, an anti-CD25 monoclonal antibody for selective depletion of regulatory T cells in the solid tumor microenvironment. As part of the deal iBio invested $7.5M in RubrYc’s Series A2 Preferred equity and joined a syndicate that includes Third Point Ventures, Paladin Capital Group, Vital Venture Capital and Hayan Health Networks. RubrYc spun out of HealthTell in 2018 and is based in San Carlos, California; the collaboration could deliver more than $84 million in milestone payments to RubrYc plus potential royalties on worldwide net sales. RubrYc Therapeutics is a biotherapeutics discovery company focused on improving drug discovery through proprietary insights into critical interactions at the drug/target interface. The company uses diverse chemical libraries developed and supplied by HealthTell to train algorithms that inform decision-making throughout drug discovery. RubrYc is building an antibody discovery platform and a proprietary pipeline of therapeutic candidates. It plans to initiate new pharmaceutical partnerships and collaborate with biotechnology companies in early drug discovery while also developing its own molecules. The company was founded in 2017 and is led by Dr. Isaac Bright (CEO) and Bill Colston (Executive Chairman). RubrYc is based in San Ramon, California.

• ImmPACT Bio

  Participated · Series A · Aug 2020

  ImmPACT Bio is a clinical-stage company based in Los Angeles developing logic-gate-based chimeric antigen receptor (CAR) T-cell therapies for cancer and autoimmune diseases. Its lead autoimmune candidate, IMPT-514, is a CD19/CD20 bispecific CAR T-cell therapy designed to deeply deplete autoreactive B cells as a one-time treatment with the potential to replace chronic immune suppression. IMPT-514 shares the same CAR construct as IMPT-314, which is under development for certain non‑Hodgkin's lymphomas. The company is evaluating IMPT-514 in an open-label Phase 1b/2 dose-escalation trial in refractory lupus nephritis (LN) and systemic lupus erythematosus (SLE), with initial efficacy and safety data expected in the second half of 2024. IMPT-514 has received FDA Fast Track designation for active and refractory LN and SLE, and preclinical work showed efficient manufacture from heavily immunosuppressed patients, potent autologous B-cell elimination, and a moderate cytokine profile. In February 2024 ImmPACT Bio was awarded an $8 million grant from the California Institute for Regenerative Medicine (CIRM) to support the ongoing Phase 1b/2 development of IMPT-514. ImmPACT Bio is a clinical-stage company developing logic-gate-based chimeric antigen receptor (CAR) T-cell therapies for cancer patients. Led by president and CEO Sumant Ramachandra, M.D., Ph.D., MBA, the company focuses on CAR T platforms designed to prevent antigen escape and reduce on-target off-tumor toxicities. Its technologies also aim to overcome the immunosuppressive tumor microenvironment. The company’s technology is based on work by Yvonne Chen and Antoni Ribas at UCLA and Gideon Gross at the MIGAL‑Galilee Research Institute. ImmPACT intends to use newly raised funds to expand the curative potential of cell therapies and to address biological challenges that have limited efficacy in hard-to-treat tumor types. The company is based in Camarillo, California and is at the clinical stage of development. ImmPACT Bio USA is a Camarillo, California–based company, founded out of the FutuRx incubator in Ness Ziona, Israel, developing novel engineered T-cell therapies for cancer. Its lead programs focus on targeting loss of genes in solid tumors using engineered T cells. The company was founded based on insights from Prof. Gideon Gross (Migal Research Institute), who collaborated with Prof. Zelig Eshhar on early CAR T technologies, and is led by CEO Rick Kendall, Ph.D. ImmPACT is advancing a set of engineered T-cell therapeutics rather than traditional CAR T constructs. The company closed a Series A equity financing in 2020 to support its development efforts. No operating metrics were disclosed in the article.

No current team members are available.